Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma
Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.